Search
News
Pre-Bell | Trump Expected to Announce Framework to Cut Health Costs, Novo Nordisk Slides 10%, Eli Lilly down 1%, Biogen up 5%; Alphabet up 3%; Tesla up 2%
Stock futures rose on Monday morning as the market seeks to rebound into the Thanksgiving holiday week after a slide that’s knocked the air out of this year’s AI bull run.Market SnapshotAt 8:20 a.m. ET, S&P 500 futures rose 0.3% and Nasdaq-100 futures increased 0.5%. Futures on the Dow Jones Industr...Tiger News
Mon, Nov 24
Chinese ETFs and ADRs Jump Premarket; WeRide up 8%; Hesai up 7%; Bilibili up 6%; Alibaba up 4%
Chinese ETFs and ADRs jumped in premarket trading on Monday.WeRide rose 8%; Hesai rose 7%; Bilibili Inc. rose 6%; Alibaba rose 4%; Baidu, NIO Inc. and XPeng Inc. rose 3%; PDD Holdings Inc and Direxion Daily FTSE China Bull 3X Shares rose 2%.
Tiger News
Mon, Nov 24
Big Techs Jump Premarket; Alphabet, Micron up 3%; Tesla, Palantir up 2%; Nvidia, Meta up 1%; Crypto Shares Gain; Hut 8 up 6%; BMNR up 5%; MARA, IREN up 4%
Big tech stocks gained in premarket trading on Monday. Alphabet, Micron rose 3%; Tesla, Broadcom, Palantir up 2%; Nvidia, AMD, Meta, Oracle up 1%.Crypto shares gained in premarket trading. Hut 8 up 6%; BMNR up 5%; MARA, IREN up 4%; Coinbase, Strategy up 3%.Global stocks began an event-filled week on...Tiger News
Mon, Nov 24
Uni-Bio Science Group Embarks on New Strategy and Launches New Website, Advancing Towards Becoming a Global Leader in Regenerative Medicine
[ Hong Kong, November 24th, 2025] Uni-Bio Science Group Limited (“Uni-Bio” or “the Group”) recently announced its official entry into a new phase of strategic development. Over the past few years, amidst profound biopharmaceutical industry transformation and multiple market challenges, the Group has consistently adhered to stable operations as its core focus, building financial resilience and commercialization capabilities. It has not only achieved sustained revenue growth and healthy cash flow, but also successfully advanced its blockbuster product – Bogutai® (Teriparatide Injection) – which was approved in China in January 2024, filling a crucial gap in its osteoporosis treatment portfolio. The Group is currently actively advancing the US FDA application for Uni-PTH, expected to be approved in 2027, and has entered a strategic collaboration with Kexing for six international markets, marking a key step in its global strategy.Building on these solid achievements, Uni-Bio has decided to shift its strategic focus comprehensively from "Stable Growth" to "Innovation-Driven." Leveraging next-generation synthetic biology and complex peptides as technological engines and focusing on the forefront of regenerative medicine, the Group is initiating a strategic leap from an "Excellent Pharmaceutical Company" to a "Global Leader in Regenerative Medicine."1. New Corporate Vision and Mission: Anchoring the Future of Regenerative MedicineAlongside this strategic upgrade, Uni-Bio announced its new corporate vision and mission, demonstrating not only its ambition to be rooted in China with a global outlook but also its deep consideration for the future of human health.Vision:" To Be the Global Leader in Regenerative Medicine, Redefining How Science Restores and Extends Human Life."Mission:"Powering the Advancement of Regenerative Medicine with Next-Generation Synthetic Biology and Complex Peptide Innovation."2. Strategic Focus Areas: Comprehensive Breakthroughs in Four Regenerative Medicine FieldsCapitalizing on its profound expertise in synthetic biology and peptide technology, Uni-Bio is building a transformative pipeline covering four key areas – Muscular-Skeletal Regeneration, Skin Regeneration, Ocular Regeneration, and ENT (Ear, Nose, and Throat) Regeneration. These areas address core unmet clinical needs and promote the transition of regenerative medicine from the laboratory to broad clinical application through the deep integration of cutting-edge technologies.(1) Muscular-Skeletal RegenerationFocus on developing osteoporosis treatment and repair products, combined with stem cell technology, to drive breakthroughs in the diagnosis and treatment of bone, cartilage, and muscle injuries and degenerative diseases. Specific projects include:UB107 (BMP-2 Biomedical Material): A key growth factor in regenerative medicine, BMP-2 can be widely used clinically for bone defect reconstruction and spinal fusion surgery. It is expected to be approved for market launch in 2028, further consolidating Uni-Bio's market share and position in the field of bone regeneration. UB106 (Novel Target Antibody for Obesity): Addressing the limitations of current obesity treatments, UB106 directly targets issues such as muscle loss, frequent dosing, gastrointestinal side effects, and pancreatitis. It is expected to be approved as early as 2030, offering a new treatment option for patients with obesity.(2) Skin RegenerationLeveraging advanced growth factor technologies and innovative delivery systems to provide precise repair solutions for burns, scalds, and hard-to-heal wounds, while also offering comprehensive solutions in the medical aesthetics field. Recently approved products include:GeneTime® (Human Epidermal Growth Factor Derivative for External Use, Liquid, 30ml large specification): Approved by the NMPA in November 2025 (Approval No.: 國藥准字 S20258020). The approval of this new specification will significantly enhance GeneTime's clinical applicability and market coverage, meeting the diverse medication needs of medical institutions at all levels and the end market. Gene Queens® (Triple Protein Repair &Balance Ampoule): This product was approved recently, further completing the Group's comprehensive "Drug & Medical Device & Cosmetic" skincare solution portfolio.(3) Ocular RegenerationUni-Bio is actively exploring the field of ocular regeneration, utilizing advanced strategies such as hEGF and anti-VEGF, to remodel ocular surface and retinal function. Through active collaborations with leading international companies and top domestic universities, the Group is advancing the R&D of potential drugs for diseases, such as age-related macular degeneration. The Group’s mission is to accelerate the translation of cutting-edge technologies into clinical applications, thereby bringing new hope to patients with ocular diseases.(4) ENT RegenerationCentered on neurotrophic factor technology, Uni-Bio is pioneering innovative R&D in ENT regeneration, The Group is exploring novel solutions for reversing hearing loss and rebuilding olfactory function, driving new breakthroughs in the restoration of ENT organ function.3. Reiterating the Firm Commitment to Innovation and CollaborationEntering this new phase of strategic development, Uni-Bio is infusing the pioneering spirit of its startup days into a higher-level mission. This transformation marks the Group's official evolution from a biopharmaceutical company with strong commercialization capabilities to a clinical-value-oriented leader in regenerative medicine driven by frontier science.Consequently, Uni-Bio will more openly embrace collaboration across industry-academia-research-medicine, international technology partnerships, and co-building a capital ecosystem. It will actively seek deep synergies with top global research institutions, clinical experts, industry partners, and investors. To communicate this strategic vision and R&D progress more transparently and efficiently, Uni-Bio has simultaneously launched a new Chinese and English official website. The new website systematically presents the Company's pipeline across the four regenerative medicine fields, its technology platforms, and milestone achievements, while also strengthening investor relations (IR) and scientific collaboration access points, aiming to become a vital bridge connecting global partners.We sincerely invite partners, investors, research colleagues, and friends from all sectors interested in the future of regenerative medicine to visit Uni-Bio's new website, delve deeper into our scientific story, and join us in participating and witnessing this journey of reshaping life through innovation.Uni-Bio Chinese Website: https://www.uni-bioscience.com/Uni-Bio English Website: https://www.uni-bioscience.com/enEndAbout Uni-Bio Science：Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2001(Stock Code: 00690.HK). The Group is committed to powering the advancement of regenerative medicine with next-generation synthetic biology and complex peptide innovation. Focusing on four core research areas—muscular-skeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration—the Group has built a diversified product pipeline encompassing innovative biologics, high-value generic drugs, and medical aesthetics. The Group operates GMP-compliant production bases in Beijing, Dongguan, and Shenzhen, with fully integrated capabilities spanning R&D, manufacturing, and commercial sales. Uni-Bio Science Group is dedicated to becoming a global leader in regenerative medicine, redefining how science restores and extends human life.24/11/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comView original content: EQS NewsEQS
Mon, Nov 24
Crypto Daily｜Tom Lee Said Strategy Stock Has Become Key Risk Management Tool; Satoshi Nakamoto's Wealth Takes a 34% Hit as Bitcoin Plummets
Crypto Daily is our column tracking crypto market trends, offering timely insights and valuable updates to keep you informed.Crypto NewsTom Lee: Strategy Stock Has Become Key Risk Management ToolBitmine Chairman and CEO Tom Lee highlighted in an interview with CBDC that due to limited on-chain optio...Tiger News
Mon, Nov 24
24H | Chinese ADRs Jump as Investors Gear up for Alibaba Earnings, US Data
Chinese ADRs jumped in overnight trading ahead of a week packed with earnings reports and a deluge of US economic data delayed by the government shutdown.WeRide rose 5%; Hesai rose 4%; NetEase and Alibaba rose 3%; Baidu and NIO rose 2%; PDD Holdings Inc and Tencent Music rose 1%.Tiger News
Mon, Nov 24
24H | Alibaba Jumps 4% as Qwen App Downloads Exceed 10 Million in First Week of Beta Testing
$Alibaba BABA)$ stock jumped 3.6% in overnight trading.Alibaba's AI assistant Qwen App has surpassed 10 million downloads in its first week of beta testing, outpacing ChatGPT, Sora, and DeepSeek to become the fastest-growing AI application in history.Tiger News
Mon, Nov 24
24H | Big Techs Jump With Alphabet, SMCI up over 2%; Tesla, Meta, Nvidia up over 1%; Crypto Shares Gain With Bakkt Holdings up 5%; IREN, Bitfarms, Bit Digital up Around 4%
Big tech stocks gained in overnight trading. Alphabet, SMCI up over 2%; Micron, Tesla, AMD, Meta, Nvidia, Palantir up over 1%; Broadcom, Oracle up within 1%.Crypto shares gained in overnight trading. Bakkt Holdings up 5%; IREN, Bitfarms, Bit Digital, GEMI, Strive up around 4%.Tiger News
Mon, Nov 24
US Stock Futures Rise as Mood Brightens, Oil Falls
US equity-index futures rose after a volatile week as optimism grew over potential Federal Reserve interest-rate cuts and reports that US officials may allow Nvidia Corp. to sell AI chips to China.Futures on the S&P 500 and Nasdaq 100 gained about 0.5% as the new week began, after the underlying gau...Tiger News
Mon, Nov 24
Ratings Weekly | Nvidia, Tesla, Apple, Alphabet, Dell, Bullish, PDD, Palo Alto Networks, and More to Watch
What has Wall Street been buzzing about this week? Here are calls made by Wall Street's best analysts during the week of Nov. 17-21.Bank of America reiterates Nvidia as buyThe firm said Nvidia remains “compelling” following earnings.“Reiterate Buy, top sector pick as AI demand continues to strengthe...Tiger News
Sun, Nov 23
Weekly Winners | Regeneron Surges 9%; Alphabet and Ross Stores Jump 8%; Medtronic Gains 6%
This week, which stocks lagged or dragged? Weekly Winners column keeps up with market trends, helping Tigers sort out the week's hottest sectors, stock winners and important news.Below are top 10 S&P 500 stock gainers for the week ended Nov. 21:Solventum to Buy Private Wound Care Firm Acera for up t...Tiger News
Sat, Nov 22
Post-Bell | U.S. Stocks Rally; Alphabet Jumps 4%; Intel Gains 3%; Apple Rises 2%; Nvidia and Tesla Fall 1%; Oracle Sinks 6%
U.S. stocks rallied on Friday as investors increased bets that the Federal Reserve will cut interest rates next month, while all three of the major indexes posted losses for the week amid concerns over lofty technology valuations.The Nasdaq fell for a third straight week in its longest run of weekly...Tiger News
Sat, Nov 22
Top Calls on Wall Street: Nvidia, Apple, IBM, Carvana, T-Mobile and More
Here are Friday’s biggest calls on Wall Street:Citi upgrades Wynn to buy from neutralAfter a change in analyst coverage, Citi upgraded the casino company and says it’s firing on all cylinders.“Meanwhile, WYNN brings the most inorganic growth potential to the table, with a major project now on the ho...Tiger News
Fri, Nov 21
Featured Tools
Top News
US Stocks End Four-Day Losing Streak, Dow Rises 500 Points; Dell Surges 12%, Oracle Reverses Gains to Fall Nearly 2% Post-Earnings
Copper Surges to Record High: Which Copper Stocks Are Worth Watching?
Salesforce vs. ServiceNow: SaaS Sees AI Turnaround, Which Has More Upside Potential, CRM or NOW?
Rent the Runway (RENT) Q2 Fiscal 2026 Earnings Call: Record Revenue and Margin Expansion
Micron Taiwan Employees Get Up to 68 Months of Pay: Will Strike Risk Ease as HBM Supply Draws Focus?
